1.05Open1.35Pre Close2 Volume268 Open Interest8.00Strike Price240.00Turnover181.56%IV0.75%PremiumNov 15, 2024Expiry Date1.28Intrinsic Value100Multiplier7DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type0.7585Delta0.1340Gamma5.62Leverage Ratio-0.0536Theta0.0010Rho4.27Eff Leverage0.0040Vega
Corvus Pharmaceuticals Stock Discussion
loading...
loading...
Corvus Pharmaceuticals Inc. carries a moderately high risk level, given its mixed fundamentals and recent volatility. Although positive analyst sentiment and a key drug catalyst suggest potential upward movement, the company's financials signal instability with negative earnings and high cash burn. The stock’s position below its 52-week high with an ongoing sector underperformance adds to the unpredictability. Moreover, the biotechnology sector can present ...
The risk associated with trading CRVS stock is moderate due to several contrasting factors. The recent price surge indicates strong market interest and price volatility, posing potential for both significant gains and unexpected reversals. While the upgrade news injects optimism, CRVS's lack of profitability presents a fundamental risk, indicating reliance on external funding rather than internal growth. Additionally, the vibrant trading volume suggests liquidit...
No comment yet